drugset

drugset / Trial / NCT04555096

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

NCT04555096 ↗

Phase 2 Terminated 16 enrolled Galera Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Trial of GC4419 in Patients with Critical Illness due to COVID-19

Timeline

Start: 2020-09-09
Primary completion: 2021-05-28
Completion: 2021-05-28

Publications

Karlsson JOG, Jynge P, Ignarro LJ. May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients? Antioxidants (Basel). 2020 Oct 10;9(10):971. doi: 10.3390/antiox9100971.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avasopasem manganese	Other / unclassified	—	Intravenous

Indications